Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals.
Francesca FaillaciLuca MarziRosina CritelliFabiola MilosaFilippo SchepisElena TurolaSilvia AndreaniGabriele VandelliVeronica BernabucciBarbara LeiFederica D'AmbrosioLaura BristotLuisa CavallettoLiliana ChemelloPamela SighinolfiPaola ManniAntonino MaioranaCristian CaporaliMarcello BianchiniMaria MarsicoLaura TurcoNicola de MariaMariagrazia Del BuonoPaola TodescaLuca di LenaDante RomagnoliPaolo MagistriFabrizio di BenedettoSavino BrunoGloria TalianiGianluigi GiannelliMaria-Luz Martinez-ChantarErica VillaPublished in: Hepatology (Baltimore, Md.) (2019)
Our study indicates that DAA-mediated increase of VEGF favors HCC recurrence/occurrence in susceptible patients, that is, those with more severe fibrosis and splanchnic collateralization, who already have abnormal activation in liver tissues of neo-angiogenetic pathways, as shown by increased ANGPT2. (Hepatology 2018; 00:000-000).
Keyphrases
- hepatitis c virus
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- gene expression
- risk assessment
- human immunodeficiency virus
- peritoneal dialysis
- vascular endothelial growth factor
- squamous cell carcinoma
- prognostic factors
- early onset
- patient reported outcomes
- squamous cell
- hiv infected